BACKGROUND: Nonorbital parameningeal sarcomas are rare, aggressive tumors that arise predominantly in the pediatric population. The purpose of this study was to review their management and to clarify the role of surgery in their treatment. METHODS: Treatment, prognostic factors, and outcomes for patients over a 10-year period were reviewed. RESULTS: In all, 34 patients were identified. The most common tumor site was the maxillary sinus, and 73% were rhabdomyosarcoma. Six patients (18%) presented with positive nodal metastases and 3 patients (10%) presented with distant metastases. Overall, 18 patients were treated surgically. Locoregional recurrence rate was 43%; no patients developed distant recurrence. Five-year overall survival was 66.8%, disease-specific survival was 68.1%, and disease-free survival was 31.9%. CONCLUSIONS: Pediatric nonorbital parameningeal sarcomas require aggressive multimodality treatment. Although chemotherapy and radiation constitute the treatment of choice in most cases, surgery may have a role as salvage therapy and in cases that fail to respond to chemoradiation.
BACKGROUND: Nonorbital parameningeal sarcomas are rare, aggressive tumors that arise predominantly in the pediatric population. The purpose of this study was to review their management and to clarify the role of surgery in their treatment. METHODS: Treatment, prognostic factors, and outcomes for patients over a 10-year period were reviewed. RESULTS: In all, 34 patients were identified. The most common tumor site was the maxillary sinus, and 73% were rhabdomyosarcoma. Six patients (18%) presented with positive nodal metastases and 3 patients (10%) presented with distant metastases. Overall, 18 patients were treated surgically. Locoregional recurrence rate was 43%; no patients developed distant recurrence. Five-year overall survival was 66.8%, disease-specific survival was 68.1%, and disease-free survival was 31.9%. CONCLUSIONS: Pediatric nonorbital parameningeal sarcomas require aggressive multimodality treatment. Although chemotherapy and radiation constitute the treatment of choice in most cases, surgery may have a role as salvage therapy and in cases that fail to respond to chemoradiation.
Authors: Sophia Marie Häußler; Carmen Stromberger; Heidi Olze; Georg Seifert; Steffen Knopke; Arne Böttcher Journal: J Cancer Res Clin Oncol Date: 2017-11-16 Impact factor: 4.553
Authors: Aileen Wertz; Brittny N Tillman; Jennifer V Brinkmeier; Tiffany A Glazer; Andrew D Kroeker; Steven E Sullivan; Erin L McKean Journal: J Neurol Surg B Skull Base Date: 2016-12-12
Authors: Adepitan A Owosho; Shih-Chiang Huang; Sonja Chen; Shruti Kashikar; Cherry L Estilo; Suzanne L Wolden; Leonard H Wexler; Joseph M Huryn; Cristina R Antonescu Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337